One-Step Duplex Droplet Digital PCR for WT1 Overexpression.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
08 2020
Historique:
received: 25 11 2019
revised: 07 05 2020
accepted: 26 05 2020
pubmed: 17 6 2020
medline: 28 8 2021
entrez: 17 6 2020
Statut: ppublish

Résumé

With the improvement of treatment methods in acute hematology malignancies, the development of sensitive tools for minimal residual disease assessment has become a priority. The monitoring of WT1 expression level by real-time quantitative PCR has been a standard for minimal residual disease evaluation in acute myeloid leukemia and, since 2009, has been optimized through a European LeukemiaNet effort in an established protocol with well-defined clinical end points. Building on the work of the European LeukemiaNet, this article reports the development of a novel, one-step duplex WT1/ABL1 droplet digital assay for WT1 overexpression detection. This assay provides accurate data with high precision and linearity, even at low-template concentration, while retaining strong correlation with the standardized method and therefore maintaining the framework to analyze the results in the context of acute myeloid leukemia patients.

Identifiants

pubmed: 32540368
pii: S1525-1578(20)30355-X
doi: 10.1016/j.jmoldx.2020.05.010
pii:
doi:

Substances chimiques

WT1 Proteins 0
WT1 protein, human 0
RNA 63231-63-0
DNA 9007-49-2
ABL1 protein, human EC 2.7.10.2
Proto-Oncogene Proteins c-abl EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1008-1019

Informations de copyright

Copyright © 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Laurent Dewispelaere (L)

Department of Molecular Hemato-Oncology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), The Free University of Brussels, Brussels, Belgium. Electronic address: laurent.dewispelaere@erasme.ulb.ac.be.

Leonore Bleret (L)

Department of Molecular Hemato-Oncology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), The Free University of Brussels, Brussels, Belgium.

Tom Van Acker (T)

Department of Molecular Hemato-Oncology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), The Free University of Brussels, Brussels, Belgium.

Cindy Van Branteghem (C)

Department of Molecular Hemato-Oncology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), The Free University of Brussels, Brussels, Belgium.

Pascale Cochaux (P)

Department of Molecular Hemato-Oncology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), The Free University of Brussels, Brussels, Belgium.

Pierre Heimann (P)

Department of Molecular Hemato-Oncology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), The Free University of Brussels, Brussels, Belgium.

Hakim El Housni (H)

Department of Molecular Hemato-Oncology, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), The Free University of Brussels, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH